| Title | Oral altretamine used as salvage therapy in recurrent ovarian cancer. | | Author(s) | Chan JK, Loizzi V, Manetta A, Berman ML | | Institution | Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305-5317, USA. | | Source | Gynecol Oncol 2004 Jan; 92(1):368-71. | | MeSH | Administration, Oral
Aged
Altretamine
Antineoplastic Agents, Alkylating
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
Ovarian Neoplasms
Salvage Therapy
| | Abstract | BACKGROUND: Altretamine has reported efficacy in the treatment of recurrent ovarian cancer following platinum-based therapy. This report presents the cases of two long-term survivors with recurrent ovarian cancer given oral altretamine. CASES: Two patients diagnosed with stage IIIC ovarian cancer underwent optimal cytoreductive surgery. Both women were subsequently treated with platinum-based chemotherapy. One had persistent cancer documented 2 months post therapy, while the other was disease-free for 22 months before recurring. Both received altretamine in a salvage setting. Each of these women achieved a prolonged response to third-line altretamine therapy, and one of whom was disease-free for 4 years and the other remains disease-free over 7 years following initiation of salvage therapy.
CONCLUSION: Outpatient-administered oral altretamine can provide a prolonged disease-free interval with minimal toxicity. | | Language | eng | | Pub Type(s) | Case Reports
Journal Article
| | PubMed ID | 14751188 |
|
